Outcome of Board Meeting held on May 22, 2026
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova Limited reported audited consolidated financial results for FY2026 ended March 31, 2026. Total revenue from operations grew 14.4% year-over-year to Rs. 82,796 million from Rs. 72,345 million. However, profit after tax declined significantly to Rs. 5,393 million from Rs. 9,433 million in the previous year, a drop of approximately 43%. The company recommended a final dividend of Rs. 5 per equity share (500% on face value of Re. 1), payable within 30 days of AGM. Statutory auditors Walker Chandiok & Co LLP issued an unmodified (clean) opinion on both standalone and consolidated financial results. The Board also approved these results at their meeting on May 22, 2026.
The stock may face pressure due to significant PAT decline despite revenue growth, though the clean audit opinion and dividend recommendation provide some shareholder reassurance. The debt levels warrant monitoring.